DLCO and Spirometry in non-small cell lung cancer patients receiving EGFR-TKI in Indonesia

1 Wang BC, Zhang WX, Kuang BH etc. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials. PLoS One 2022;17(10):e0275919. Search in Google Scholar

2 Harada C, Kawaguchi T, Ogata-Suetsugu S etc. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med 2011;183(6):743-751. Search in Google Scholar

3 Gemma A, Kudoh S, Ando M etc. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci 2014;105(12):1584-1590. Search in Google Scholar

4 Muller NL, White DA, Jiang H etc. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91 Suppl 2(Suppl 2):S24-30. Search in Google Scholar

5 Chang SC, Chang CY, Chang SJ etc. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer. Clin Lung Cancer 2013;14(1):55-61. Search in Google Scholar

6 Graham BL, Steenbruggen I, Miller MR etc. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019;200(8):e70-e88. Search in Google Scholar

7 Graham BL, Brusasco V, Burgos F etc. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 2017;49(1). Search in Google Scholar

8 Shi Y, Li J, Zhang S etc. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One 2015;10(11):e0143515. Search in Google Scholar

9 Sequist LV, Yang JC, Yamamoto N etc. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27):3327-3334. Search in Google Scholar

10 Fathana FB, Yunus F, Andarini SL etc. Prevalens penyakit paru obstruksi kronik (PPOK) dan emfisema berdasarkan pemeriksaan spirometri dan Computed Tomography Scanning (CT-Scan) toraks pada pasien kanker paru di Rumah Sakit Umum Pusat Persahabatan. Jakarta, Indonesia: University of Indonesia; 2019. Search in Google Scholar

11 Leo F, Solli P, Spaggiari L etc. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004;77(1):260-265; discussion 265. Search in Google Scholar

12 Takeda S, Funakoshi Y, Kadota Y etc. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? Ann Thorac Surg 2006;82(1):232-236. Search in Google Scholar

13 Pinson P, Klastersky J. The value of lung function measurements for the assessment of chemotherapy in lung cancer patients. Lung Cancer 1998;19(3):179-184. Search in Google Scholar

14 Yang Z, Hackshaw A, Feng Q etc. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer 2017;140(12):2805-2819. Search in Google Scholar

15 Lim SH, Lee JY, Sun JM etc. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. J Thorac Oncol 2014;9(4):506-511. Search in Google Scholar

16 Wu SG, Chang YL, Yu CJ etc. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res 2017;3(3). Search in Google Scholar

17 Bailey KL. The importance of the assessment of pulmonary function in COPD. Med Clin North Am 2012;96(4):745-752. Search in Google Scholar